Mario Barugel

5.5k total citations · 1 hit paper
29 papers, 1.8k citations indexed

About

Mario Barugel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mario Barugel has authored 29 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Mario Barugel's work include Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (6 papers) and Genetic factors in colorectal cancer (5 papers). Mario Barugel is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (6 papers) and Genetic factors in colorectal cancer (5 papers). Mario Barugel collaborates with scholars based in Argentina, Belgium and United Kingdom. Mario Barugel's co-authors include David Cunningham, Josep Tabernero, Salvatore Siena, Jean‐Yves Douillard, Ronald L. Burkes, Yves Humblet, Jennifer Gansert, Fernando Rivera, Jacek Jassem and Martin Šmakal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Mario Barugel

29 papers receiving 1.7k citations

Hit Papers

Randomized, Phase III Trial of Panitumumab With Infusiona... 2010 2026 2015 2020 2010 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
    2010 1.4k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mario Barugel Argentina 13 1.5k 695 416 408 398 29 1.8k
Ірина Давиденко United States 16 807 0.5× 583 0.8× 286 0.7× 432 1.1× 284 0.7× 33 1.6k
Joseph J. Schulz United States 6 1.3k 0.9× 533 0.8× 148 0.4× 469 1.1× 195 0.5× 8 1.5k
Janja Ocvirk Slovenia 17 1.0k 0.7× 376 0.5× 179 0.4× 226 0.6× 231 0.6× 69 1.3k
Salvatore Artale Italy 18 1.9k 1.2× 648 0.9× 324 0.8× 183 0.4× 780 2.0× 41 2.3k
Joe McKendrick Australia 7 865 0.6× 420 0.6× 176 0.4× 292 0.7× 170 0.4× 9 1.1k
Rosella Spadi Italy 13 1.1k 0.7× 489 0.7× 193 0.5× 324 0.8× 358 0.9× 28 1.4k
G. Des Guetz France 20 1.2k 0.8× 481 0.7× 492 1.2× 84 0.2× 335 0.8× 72 1.6k
Silvia Mezi Italy 15 1.0k 0.7× 416 0.6× 292 0.7× 222 0.5× 240 0.6× 51 1.4k
C. Schlichting Germany 9 822 0.5× 405 0.6× 142 0.3× 297 0.7× 152 0.4× 16 1.2k
Lorenzo Fornaro Italy 23 1.7k 1.1× 935 1.3× 329 0.8× 587 1.4× 760 1.9× 133 2.5k

Countries citing papers authored by Mario Barugel

Since Specialization
Citations

This map shows the geographic impact of Mario Barugel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Barugel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Barugel more than expected).

Fields of papers citing papers by Mario Barugel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Barugel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Barugel. The network helps show where Mario Barugel may publish in the future.

Co-authorship network of co-authors of Mario Barugel

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Barugel. A scholar is included among the top collaborators of Mario Barugel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Barugel. Mario Barugel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iseas, Soledad, et al.. (2016). P-127 Pathological versus clinical complete responders after preoperative treatment in rectal cancer: long term outcomes analysis. Annals of Oncology. 27. ii37–ii37. 1 indexed citations
2.
Carballido, Marcela, et al.. (2015). Moving foward and beyond the standard through a non-operative management in rectal cancer? Our watch and wait approach experience in Co-Recto.. Journal of Clinical Oncology. 33(15_suppl). 3561–3561. 2 indexed citations
3.
Oliner, Kelly S., Jean‐Yves Douillard, Salvatore Siena, et al.. (2013). Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC). Annals of Oncology. 24. iv23–iv24. 2 indexed citations
4.
Oliner, Kelly S., Jean‐Yves Douillard, Salvatore Siena, et al.. (2013). Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 31(15_suppl). 3511–3511. 42 indexed citations
5.
Douillard, Jean-Yves, Salvatore Siena, Josep Tabernero, et al.. (2012). Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(4_suppl). 531–531. 22 indexed citations
6.
7.
8.
Douillard, Jean‐Yves, Salvatore Siena, James T. Cassidy, et al.. (2010). Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology. 28(31). 4697–4705. 1351 indexed citations breakdown →
9.
Siena, Salvatore, Jean‐Yves Douillard, James T. Cassidy, et al.. (2010). Prime study : a randomised phase 3 study of panitumumab with Folfox4 versus Folfox4 alone as first line treatment for metastatic colorectal cancer (mCRC). Annals of Oncology. 21. 1 indexed citations
10.
Barugel, Mario, et al.. (2009). Metastatic colorectal cancer: recent advances in its clinical management. Expert Review of Anticancer Therapy. 9(12). 1829–1847. 21 indexed citations
11.
Douillard, Jean‐Yves, Salvatore Siena, Josep Tabernero, et al.. (2009). 10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. European Journal of Cancer Supplements. 7(3). 6–6. 63 indexed citations
12.
Sambuelli, Alicia M., et al.. (2005). Prevención del cáncer colorrectal (CCR). SHILAP Revista de lepidopterología. 35(2). 104–140. 1 indexed citations
13.
Sambuelli, Alicia M., et al.. (2005). [Prevention of colorectal cancer].. PubMed. 35(2). 104–40. 2 indexed citations
14.
Chacón, Matías, Enrique Roca, Mario Barugel, et al.. (2004). Report of solid cancer in patients (pts) with gastrointestinal stromal tumours (GIST). Journal of Clinical Oncology. 22(14_suppl). 9065–9065. 2 indexed citations
15.
Chacón, Matías, Enrique Roca, Mario Barugel, et al.. (2004). Report of solid cancer in patients (pts) with gastrointestinal stromal tumours (GIST). Journal of Clinical Oncology. 22(14_suppl). 9065–9065. 12 indexed citations
16.
Carraro, Silvia, Enrique Roca, Ernesto Wasserman, et al.. (2002). Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3–T4 unresectable rectal cancer: a phase II IATTGI study. International Journal of Radiation Oncology*Biology*Physics. 54(2). 397–402. 58 indexed citations
17.
Roca, Enrique, Eduardo J. Pennella, Silvia Carraro, et al.. (1996). Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer. European Journal of Cancer. 32(3). 429–432. 19 indexed citations
18.
Roca, Enrique, et al.. (1995). [Medical treatment of 44 patients with anal canal carcinoma. Argentinian Intergroup for the treatment of gastrointestinal tumors (IATTGI)].. PubMed. 55(3). 243–8. 1 indexed citations
19.
Bruera, Éduardo, Samuela Carraro, Enrique Roca, Mario Barugel, & R. Chacón. (1986). Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients.. PubMed. 70(2). 295–8. 37 indexed citations
20.
Roca, Elisa, Éduardo Bruera, Pedro M. Politi, et al.. (1985). Vinca alkaloid-induced cardiovascular autonomic neuropathy.. PubMed. 69(2). 149–51. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ірина Давиденко Breakdown of academic impact, for papers by Joseph J. Schulz Breakdown of academic impact, for papers by Janja Ocvirk Breakdown of academic impact, for papers by Salvatore Artale Breakdown of academic impact, for papers by Joe McKendrick Breakdown of academic impact, for papers by Rosella Spadi Breakdown of academic impact, for papers by G. Des Guetz Breakdown of academic impact, for papers by Silvia Mezi Breakdown of academic impact, for papers by C. Schlichting Breakdown of academic impact, for papers by Lorenzo Fornaro
Rankless by CCL
2026